asparaginase Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
enzymes 5070 9015-68-3

Description:

MoleculeDescription

Synonyms:

  • asparaginase
  • elspar
A hydrolase enzyme that converts L-asparagine and water to L-aspartate and NH3. EC 3.5.1.1.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Feb. 1, 1994 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Venoocclusive liver disease 276.35 29.82 69 5080 4182 46676731
Febrile neutropenia 267.55 29.82 152 4997 94475 46586438
Posterior reversible encephalopathy syndrome 182.45 29.82 67 5082 15074 46665839
Temporal lobe epilepsy 180.31 29.82 32 5117 351 46680562
Lennox-Gastaut syndrome 169.93 29.82 29 5120 248 46680665
Osteonecrosis 167.34 29.82 73 5076 25671 46655242
Acute lymphocytic leukaemia recurrent 146.11 29.82 36 5113 2059 46678854
Haematotoxicity 135.26 29.82 44 5105 6889 46674024
Pneumatosis intestinalis 97.97 29.82 26 5123 1999 46678914
Neurotoxicity 95.95 29.82 41 5108 13676 46667237
Philadelphia chromosome positive 83.01 29.82 16 5133 283 46680630
Neutropenia 82.95 29.82 90 5059 143114 46537799
Bone marrow failure 81.70 29.82 47 5102 29622 46651291
Mucormycosis 81.05 29.82 23 5126 2269 46678644
Human bocavirus infection 80.73 29.82 16 5133 329 46680584
Secondary immunodeficiency 79.23 29.82 19 5130 968 46679945
Partial seizures 74.75 29.82 26 5123 4984 46675929
Drug interaction 74.12 29.82 101 5048 202993 46477920
Cerebral venous sinus thrombosis 72.22 29.82 20 5129 1805 46679108
Drug resistance 65.81 29.82 34 5115 17334 46663579
Cerebral venous thrombosis 64.76 29.82 19 5130 2108 46678805
Enterobacter infection 62.52 29.82 18 5131 1869 46679044
Therapeutic response delayed 62.29 29.82 14 5135 535 46680378
Leukaemia recurrent 59.50 29.82 16 5133 1293 46679620
Hepatotoxicity 54.25 29.82 34 5115 24975 46655938
Gastroenteritis norovirus 52.09 29.82 15 5134 1558 46679355
Herpes simplex 51.85 29.82 22 5127 7201 46673712
Acute lymphocytic leukaemia 51.64 29.82 17 5132 2756 46678157
Neuropathy peripheral 50.57 29.82 56 5093 90837 46590076
Venous thrombosis 49.74 29.82 19 5130 4743 46676170
Human herpesvirus 6 infection 49.66 29.82 16 5133 2423 46678490
Febrile bone marrow aplasia 49.58 29.82 21 5128 6841 46674072
Ileus paralytic 47.87 29.82 18 5131 4305 46676608
Aplasia 47.40 29.82 17 5132 3559 46677354
Hypertriglyceridaemia 46.41 29.82 19 5130 5685 46675228
Mucosal inflammation 44.90 29.82 36 5113 38940 46641973
Rhinovirus infection 43.41 29.82 16 5133 3620 46677293
Clostridium difficile colitis 42.20 29.82 26 5123 18527 46662386
Superior sagittal sinus thrombosis 41.42 29.82 11 5138 847 46680066
Encephalopathy 40.78 29.82 32 5117 33557 46647356
Simple partial seizures 40.73 29.82 10 5139 562 46680351
Pancreatic pseudocyst 40.61 29.82 10 5139 569 46680344
Leukoencephalopathy 38.34 29.82 15 5134 3989 46676924
Pancytopenia 38.26 29.82 47 5102 85011 46595902
Quadriplegia 37.85 29.82 12 5137 1725 46679188
Myelopathy 37.12 29.82 13 5136 2539 46678374
Sepsis 36.99 29.82 59 5090 135955 46544958
Enteritis 36.94 29.82 17 5132 6738 46674175
Epilepsy 36.36 29.82 26 5123 23712 46657201
Antithrombin III decreased 36.08 29.82 8 5141 287 46680626
Multiple organ dysfunction syndrome 34.29 29.82 35 5114 51675 46629238
Neoplasm recurrence 34.18 29.82 12 5137 2361 46678552
Cardiotoxicity 33.91 29.82 16 5133 6706 46674207
Pain 33.79 29.82 6 5143 476942 46203971
Blood fibrinogen decreased 33.79 29.82 9 5140 701 46680212
Nausea 33.74 29.82 17 5132 687437 45993476
Mutism 32.60 29.82 10 5139 1290 46679623
Venoocclusive disease 32.48 29.82 11 5138 1945 46678968
Graft versus host disease 31.16 29.82 15 5134 6573 46674340
Haemorrhagic infarction 30.61 29.82 7 5142 289 46680624
Aspergillus infection 30.52 29.82 15 5134 6875 46674038

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 275.05 27.24 207 6196 106486 29839589
Posterior reversible encephalopathy syndrome 253.78 27.24 88 6315 8619 29937456
Venoocclusive liver disease 185.56 27.24 65 6338 6548 29939527
Haematotoxicity 178.33 27.24 62 6341 6108 29939967
Neutropenia 157.93 27.24 164 6239 128376 29817699
Osteonecrosis 147.55 27.24 71 6332 16064 29930011
Mucosal inflammation 98.26 27.24 68 6335 30426 29915649
Multiple organ dysfunction syndrome 86.77 27.24 86 6317 63401 29882674
Multiple-drug resistance 82.80 27.24 29 6374 2912 29943163
Mucormycosis 79.67 27.24 33 6370 5235 29940840
Superior sagittal sinus thrombosis 77.28 27.24 17 6386 295 29945780
Bone marrow failure 67.99 27.24 54 6349 29731 29916344
Venoocclusive disease 63.31 27.24 23 6380 2567 29943508
Acute lymphocytic leukaemia recurrent 58.97 27.24 22 6381 2645 29943430
Glioma 55.34 27.24 13 6390 306 29945769
Minimal residual disease 53.52 27.24 12 6391 228 29945847
Acute lymphocytic leukaemia 52.46 27.24 21 6382 3051 29943024
Seizure 49.48 27.24 81 6322 98394 29847681
Haemophagocytic lymphohistiocytosis 49.38 27.24 29 6374 9762 29936313
Fatigue 48.24 27.24 6 6397 320667 29625408
Cerebral venous thrombosis 47.03 27.24 13 6390 594 29945481
Aspergillus infection 45.67 27.24 28 6375 10186 29935889
Aspiration bone marrow abnormal 44.48 27.24 9 6394 102 29945973
Septic shock 44.33 27.24 61 6342 63546 29882529
Large intestine infection 41.14 27.24 14 6389 1289 29944786
Stomatitis 40.98 27.24 45 6358 37234 29908841
Hypertriglyceridaemia 40.87 27.24 24 6379 8074 29938001
Adenoviral hepatitis 40.55 27.24 9 6394 163 29945912
Myelopathy 39.20 27.24 15 6388 1932 29944143
Encephalopathy 39.13 27.24 41 6362 32164 29913911
Candida endophthalmitis 38.89 27.24 8 6395 99 29945976
Pancytopenia 38.76 27.24 67 6336 84985 29861090
Systemic mycosis 38.13 27.24 13 6390 1203 29944872
Antithrombin III decreased 37.86 27.24 10 6393 384 29945691
Congenital herpes simplex infection 37.25 27.24 7 6396 52 29946023
Febrile bone marrow aplasia 35.70 27.24 22 6381 8075 29938000
Glioblastoma multiforme 34.16 27.24 11 6392 852 29945223
Fungal infection 33.91 27.24 26 6377 13574 29932501
Inappropriate antidiuretic hormone secretion 33.33 27.24 24 6379 11398 29934677
Leukopenia 32.03 27.24 49 6354 56110 29889965
Hepatocellular injury 31.96 27.24 33 6370 25438 29920637
Leukaemia recurrent 31.33 27.24 12 6391 1549 29944526
Oesophageal stenosis 31.17 27.24 12 6391 1571 29944504
Pyrexia 30.58 27.24 134 6269 294355 29651720
Acute monocytic leukaemia 29.00 27.24 8 6395 363 29945712
T-cell type acute leukaemia 28.98 27.24 7 6396 186 29945889
Precursor T-lymphoblastic lymphoma/leukaemia 28.68 27.24 6 6397 81 29945994
Sepsis 28.48 27.24 82 6321 146313 29799762
Hip deformity 28.15 27.24 6 6397 89 29945986
Hepatic steatosis 27.84 27.24 24 6379 14769 29931306
Systemic candida 27.79 27.24 13 6390 2751 29943324
Bronchopulmonary aspergillosis 27.42 27.24 22 6381 12262 29933813

Pharmacologic Action:

SourceCodeDescription
ATC L01XX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
FDA CS M0001815 Asparaginase
FDA EPC N0000175669 Asparagine-specific Enzyme
MeSH PA D000970 Antineoplastic Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Acute lymphoid leukemia indication 91857003 DOID:9952

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
aspargine Amino acid HYDROLYTIC ENZYME DRUG LABEL DRUG LABEL

External reference:

IDSource
G4FQ3CKY5R UNII
4017974 VANDF
C0003993 UMLSCUI
CHEMBL2108989 ChEMBL_ID
DB00023 DRUGBANK_ID
D001215 MESH_DESCRIPTOR_UI
5460875 PUBCHEM_CID
1156 RXNORM
4222 MMSL
688 MMSL
002673 NDDF
18811003 SNOMEDCT_US
370969007 SNOMEDCT_US
371014004 SNOMEDCT_US

Pharmaceutical products:

None